论文部分内容阅读
目的 观察蚓激酶胶囊治疗急性缺血性脑梗死的疗效。方法 将120例急性脑梗死病人随机分为两组,蚓激酶60例(男性40例,女性20例,年龄59±12a),予蚓激酶胶囊460mg,po,tid,复方丹参注射液20ml+5％葡萄糖注射液500ml,静脉滴注,qd,疗程均为14～28天。结果 蚓激酶组显效率80％,对照组45％,两组疗效经Ridit分析,有显著性差异(P<0.05);蚓激酶组的血流变学指标有显著性改变(P<0.05)。结论蚓激酶胶囊口服加复方丹参注射液组治疗脑梗死疗效优于复方丹参注射液组,蚓激酶对治疗脑梗死有较好疗效。
Objective To observe the efficacy of lumbrokinase capsules in the treatment of acute ischemic cerebral infarction. Methods 120 patients with acute cerebral infarction were randomly divided into two groups: 60 patients (40 males and 20 females, age 59 ± 12 years), Lumbrokinase capsules 460mg, po, tid, compound Danshen injection 20ml +5 % Glucose injection 500ml, intravenous infusion, qd, treatment are 14 to 28 days. Results Lumbrokinase was markedly effective in 80% of the control group and 45% of the control group. There was a significant difference (P <0.05) between the two groups by Ridit analysis. The hemorrheological parameters of lumbrokinase group were significantly changed (P <0.05). Conclusion Lumbukinase capsule plus compound salvia miltiorrhiza injection group is better than compound Salvia miltiorrhiza injection group in the treatment of cerebral infarction. Lumbrokinase is effective in treating cerebral infarction.